BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 11, 2025
Home » Authors » Haky Moon

Haky Moon

Articles

ARTICLES

Alteogen set to start phase I testing for Herceptin biosimilar

March 2, 2016
By Haky Moon
HONG KONG – A green light to launch clinical trials in Canada for one of its leading biosimilar products will give South Korean company Alteogen Inc. and its Brazilian partner a boost on the global market.
Read More

Industry turns to South Korean officials to boost biopharma

Feb. 25, 2016
By Haky Moon
HONG KONG – South Korean biopharma companies are urging the government to speed up the implementation of supporting policies, particularly tax policies that could make it easier for young bioventures to become competitive.
Read More

Samsung spearheads Korean efforts to develop MERS vaccine

Feb. 24, 2016
By Haky Moon
HONG KONG – South Korea's Samsung conglomerate is pouring tens of millions into Middle East respiratory syndrome (MERS) research, less than a year after an oversight at one of the company's hospitals facilitated the spread of the deadly virus.
Read More

Samsung spearheads Korean efforts to develop MERS vaccine

Feb. 24, 2016
By Haky Moon
HONG KONG – South Korea's Samsung conglomerate is pouring tens of millions into Middle East respiratory syndrome (MERS) research, less than a year after an oversight at one of the company's hospitals facilitated the spread of the deadly virus.
Read More

Industry turns to South Korean officials to boost biopharma

Feb. 24, 2016
By Haky Moon
HONG KONG – South Korean biopharma companies are urging the government to speed up the implementation of supporting policies, particularly tax policies that could make it easier for young bioventures to become competitive.
Read More

Biotronik building first Asia-Pacific plant in Singapore

Feb. 23, 2016
By Haky Moon

Asian countries pushing for more comprehensive mobile health regulations

Feb. 11, 2016
By Haky Moon

Labgenomics aggressively expands into global markets

Feb. 8, 2016
By Haky Moon

'A lot of firsts,' as Korean firm Viromed advances gene therapy

Feb. 3, 2016
By Haky Moon
HONG KONG – With the successful completion of a phase II study in the U.S. for its flagship product, VM202, for the treatment of critical limb ischemia (CLI), South Korean biopharma Viromed Co. Ltd. is off to a good start this year.
Read More

South Korea continues to boost biopharma sector, tightening review process

Feb. 3, 2016
By Haky Moon
HONG KONG – The Korean Ministry of Food and Drug Safety (MFDS) is shortening the biologics review process for rare and incurable diseases to speed up the approvals and overseas distribution of Korea-developed biopharmaceuticals. Although details of the policy are sketchy and yet to be disclosed, the announcement marks the country's determination to make biopharmaceuticals a core industry.
Read More
View All Articles by Haky Moon

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing